PT2516406E - Agonistas de mglu2 - Google Patents

Agonistas de mglu2

Info

Publication number
PT2516406E
PT2516406E PT107984197T PT10798419T PT2516406E PT 2516406 E PT2516406 E PT 2516406E PT 107984197 T PT107984197 T PT 107984197T PT 10798419 T PT10798419 T PT 10798419T PT 2516406 E PT2516406 E PT 2516406E
Authority
PT
Portugal
Prior art keywords
mglu2 agonists
mglu2
agonists
schizophrenia
depression
Prior art date
Application number
PT107984197T
Other languages
English (en)
Inventor
James Allen Monn
Lourdes Prieto
Lorena Taboada Martinez
Carlos Montero Salgado
Bruce William Shaw
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42026702&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2516406(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT2516406E publication Critical patent/PT2516406E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D249/12Oxygen or sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C07D249/101,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41961,2,4-Triazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PT107984197T 2009-12-21 2010-12-15 Agonistas de mglu2 PT2516406E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09382290 2009-12-21
US30523910P 2010-02-17 2010-02-17

Publications (1)

Publication Number Publication Date
PT2516406E true PT2516406E (pt) 2013-10-10

Family

ID=42026702

Family Applications (1)

Application Number Title Priority Date Filing Date
PT107984197T PT2516406E (pt) 2009-12-21 2010-12-15 Agonistas de mglu2

Country Status (35)

Country Link
US (1) US8318184B2 (pt)
EP (1) EP2516406B1 (pt)
JP (1) JP5779190B2 (pt)
KR (1) KR101395356B1 (pt)
CN (1) CN102695701B (pt)
AR (1) AR079343A1 (pt)
AU (1) AU2010340039B2 (pt)
BR (1) BR112012017188B1 (pt)
CA (1) CA2784667C (pt)
CR (1) CR20120322A (pt)
CY (1) CY1114880T1 (pt)
DK (1) DK2516406T3 (pt)
DO (1) DOP2012000173A (pt)
EA (1) EA020229B1 (pt)
EC (1) ECSP12011989A (pt)
ES (1) ES2435651T3 (pt)
HK (1) HK1171228A1 (pt)
HN (1) HN2012001160A (pt)
HR (1) HRP20131052T1 (pt)
IL (1) IL220011A (pt)
JO (1) JO2978B1 (pt)
MA (1) MA33824B1 (pt)
MX (1) MX2012007332A (pt)
MY (1) MY160618A (pt)
NZ (1) NZ600305A (pt)
PE (1) PE20121688A1 (pt)
PL (1) PL2516406T3 (pt)
PT (1) PT2516406E (pt)
RS (1) RS53063B (pt)
SG (1) SG181836A1 (pt)
SI (1) SI2516406T1 (pt)
TN (1) TN2012000281A1 (pt)
TW (1) TWI477490B (pt)
UA (1) UA107684C2 (pt)
WO (1) WO2011084437A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG183304A1 (en) 2010-02-17 2012-09-27 Takeda Pharmaceutical Heterocyclic compound
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
BR112013012384A2 (pt) * 2010-11-18 2019-09-24 Lilly Co Eli compostos 3-benzilóóxi-biciclo[3.1.0]hexano 4-substituídos como antagonistas receptores de mglu2 e mglu3
EA023553B1 (ru) * 2011-06-17 2016-06-30 Эли Лилли Энд Компани Агонисты рецептора mglu2
AR089718A1 (es) * 2012-02-01 2014-09-10 Lilly Co Eli AGONISTAS DE mGlu2/3
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
HUE053734T2 (hu) 2014-01-21 2021-07-28 Janssen Pharmaceutica Nv 2-es altípusú metabotróp glutamáterg receptor pozitív allosztérikus modulátorait tartalmazó kombinációk és alkalmazásuk
EA201891617A3 (ru) * 2014-01-21 2019-04-30 Янссен Фармацевтика Нв Комбинации, содержащие положительные аллостерические модуляторы или ортостерические агонисты метаботропного глутаматергического рецептора 2 подтипа, и их применение
US11324734B2 (en) 2015-04-01 2022-05-10 Akebia Therapeutics, Inc. Compositions and methods for treating anemia

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576323A (en) * 1993-12-03 1996-11-19 Eli Lilly And Company Excitatory amino acid receptor antagonists
US5688826A (en) * 1995-11-16 1997-11-18 Eli Lilly And Company Excitatory amino acid derivatives
GB9605429D0 (en) * 1995-11-16 1996-05-15 Lilly Co Eli Excitatory amino acid receptor antagonists
ZA983930B (en) 1997-05-14 1999-11-08 Lilly Co Eli Excitatory amino acid receptor modulators.
WO2002055485A1 (en) * 2001-01-11 2002-07-18 Eli Lilly And Company Prodrugs of excitatory amino acids
HUP0400620A3 (en) * 2001-01-11 2012-09-28 Lilly Co Eli Prodrugs of excitatory amino acids and pharmaceutical compositions containing them and process for preparation the compounds
WO2002068380A1 (en) * 2001-02-22 2002-09-06 Eli Lilly And Company Synthetic excitatory amino acids
BR0311558A (pt) * 2002-06-11 2007-04-27 Lilly Co Eli composto ou sal farmaceuticamente aceitável do mesmo, processo para preparar o mesmo, métodos para afetar os receptores de glutamato metabotrópicos ligados a camp, para administrar uma quantidade eficaz de um composto e para tratar um distúrbio neurológico e psiquiátrico em um paciente, e, formulação farmacêutica
US7381746B2 (en) * 2003-06-26 2008-06-03 Taisho Pharmaceutical Co., Ltd. 2-Aminobicyclo[3.1.0]hexane-2,6-dicarboxylic acid derivative
TWI520935B (zh) * 2010-11-18 2016-02-11 美國禮來大藥廠 作為mGluR2/3拮抗劑之4-經取代-3-苯基磺醯基甲基-雙環[3.1.0]己烷化合物
BR112013012384A2 (pt) * 2010-11-18 2019-09-24 Lilly Co Eli compostos 3-benzilóóxi-biciclo[3.1.0]hexano 4-substituídos como antagonistas receptores de mglu2 e mglu3

Also Published As

Publication number Publication date
PE20121688A1 (es) 2012-12-05
EP2516406B1 (en) 2013-09-18
BR112012017188B1 (pt) 2021-06-22
KR20120094056A (ko) 2012-08-23
JP2013514974A (ja) 2013-05-02
SI2516406T1 (sl) 2013-11-29
PL2516406T3 (pl) 2014-03-31
DOP2012000173A (es) 2012-11-30
HK1171228A1 (en) 2013-03-22
AU2010340039B2 (en) 2014-03-20
IL220011A (en) 2014-03-31
JO2978B1 (en) 2016-03-15
TN2012000281A1 (en) 2013-12-12
CR20120322A (es) 2012-07-10
MX2012007332A (es) 2012-07-20
AR079343A1 (es) 2012-01-18
SG181836A1 (en) 2012-08-30
HN2012001160A (es) 2015-08-24
US8318184B2 (en) 2012-11-27
BR112012017188A2 (pt) 2016-03-22
HRP20131052T1 (hr) 2013-12-06
TWI477490B (zh) 2015-03-21
DK2516406T3 (da) 2013-10-14
TW201144290A (en) 2011-12-16
JP5779190B2 (ja) 2015-09-16
MY160618A (en) 2017-03-15
EA201290558A1 (ru) 2012-12-28
CN102695701A (zh) 2012-09-26
ES2435651T3 (es) 2013-12-20
CA2784667C (en) 2014-11-18
CY1114880T1 (el) 2016-12-14
IL220011A0 (en) 2012-07-31
CA2784667A1 (en) 2011-07-14
AU2010340039A1 (en) 2012-08-09
RS53063B (en) 2014-04-30
WO2011084437A1 (en) 2011-07-14
CN102695701B (zh) 2014-10-01
EP2516406A1 (en) 2012-10-31
ECSP12011989A (es) 2012-07-31
KR101395356B1 (ko) 2014-05-14
US20110152334A1 (en) 2011-06-23
NZ600305A (en) 2014-01-31
UA107684C2 (xx) 2015-02-10
EA020229B1 (ru) 2014-09-30
BR112012017188A8 (pt) 2016-10-04
MA33824B1 (fr) 2012-12-03

Similar Documents

Publication Publication Date Title
MY160618A (en) Mglu2 agonists
MY179933A (en) Certain triazolopyridines and triazolopyrazines, compositions thereof and methods of use thereof
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
TN2011000673A1 (en) Bace inhibitors
MX345909B (es) Anticuerpos anti-fgfr3 y métodos que los utilizan.
MX357820B (es) Composiciones para uso en la manufactura de medicamentos para tratamiento de esclerosis multiple progresiva.
EA201171367A1 (ru) Винилиндазолильные соединения
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
EA201270619A1 (ru) Применение бетанехола для лечения ксеростомии
MX2013001473A (es) Anticuerpos contra il-18r1 y usos de los mismos.
MX2013002784A (es) Heteroarilos fusionados y sus usos.
CR20120362A (es) Ciertas triazolopiridinas y triazolopirazinas, composiciones de estas y sus métodos de empleo
MY143269A (en) Use of agomelatine in obtaining medicaments intended for the treatment of generalized anxiety disorder
CR20110361A (es) Derivados de 2-piridin-2-il-pirazol-3(2h)-ona, su preparación y su aplicación en terapeutica como activadores de hif
CL2008001837A1 (es) Uso de compuestos derivados de cinolin-3-carboxamida en el tratamiento de la esquizofrenia.
EP2533796A4 (en) METHOD FOR THE TREATMENT OF GLUCOSE TISSUE CHANGES
EA201391700A1 (ru) АГОНИСТЫ РЕЦЕПТОРА mGlu2
UA41660U (en) Use of jacton and mexidol as actoprotector
UA44978U (en) 2,8-dimethyl-3-dymethylaminomethylquinolione-4-on possessing anxiolytic and antiamnestic activities
UA35660U (en) Use of antihomotoxic preparations as cytoprotectors
UA41922U (ru) Применение альтана как вещества с противолучевыми свойствами
UA52379U (ru) Применение ЛИПИНА в качестве средства фригопротекторного действия
UA52376U (ru) Применение КОРВИТИНА в качестве средства фригопротекторного действия
UA52378U (ru) Применение ЛИПОФЛАВОНА в качестве средства фригопротекторного действия
UA70698U (ru) Применение 2-метил-3-фениламинометилхинолин-4-она как противогипоксического, актопротекторного и антиалкогольного средства